Thiophenytoin

Thiophenytoin

SCHEMBL1685397

O=C1NC(=S)NC1(c1ccccc1)c1ccccc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.64
MAPT P10636 2/20 0.64
BLM P54132 2/20 0.64
PMP22 Q01453 2/20 0.64
CACNA1F O60840 1/20 0.64
ALDH1A1 P00352 1/20 0.64
HTR2A P28223 1/20 0.64
HRH1 P35367 1/20 0.64
SCN1A P35498 1/20 0.64
SCN4A P35499 1/20 0.64
CACNA1D Q01668 1/20 0.64
KCNH2 Q12809 1/20 0.64
CACNA1S Q13698 1/20 0.64
CACNA1C Q13936 1/20 0.64
SCN5A Q14524 1/20 0.64
SCN2A Q99250 1/20 0.64
SCN3A Q9NY46 1/20 0.64
AKR1B1 P15121 1/20 0.53
GAA P10253 1/20 0.43
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31318280 0.80 CNR1 (0.48) CYP2C9MAPTBLMPMP22CACNA1F
SCHEMBL7488088 0.78 CYP2C9 (0.42) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL3440 0.78 CYP2C9 (1.00) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL5499612 0.78 CYP2C9 (1.00) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL157671 0.77 CYP2C9 (0.96) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL2905857 0.77 CYP2C9 (0.96) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL5160618 0.77 CYP2C9 (0.96) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL10406406 0.77 CYP2C9 (0.96) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL2140317 0.77 CYP2C9 (0.96) CYP2C9MAPTBLMPMP22CACNA1F
Phenytoin SCHEMBL1461588 0.77 CYP2C9 (0.96) CYP2C9MAPTBLMPMP22CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4095097-B1 METAL-ADSORBING COMPOSITE MATERIAL BASED ON MAGNETIC GRAPHENE OXIDE AND METHOD FOR OBTAINING SAME UNIV MALAGA (ES) 2025-10-01 EP claimed
CN-116088516-B Three-dimensional path planning method for underwater vehicle based on improved particle swarm optimization 中国人民解放军国防科技大学 2025-06-13 CN claimed
US-20250163482-A1 NOVEL SYNTHETIC PROMOTER, AND METHOD FOR PRODUCING DAPTOMYCIN USING SAME KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP (KR) 2025-05-22 US claimed
CN-119990803-A Mine resource exploitation design system based on big data 山金设计咨询有限公司 2025-05-13 CN claimed
CN-119541790-A Intelligent follow-up visit management system for skin disease patients 独单信息科技集团有限公司 2025-02-28 CN claimed
CN-115061039-B Method for evaluating characteristics of internal terminals of high-voltage circuit breaker and related equipment 云南电网有限责任公司电力科学研究院 2024-09-24 CN claimed
CN-118028333-A Method for improving conversion efficiency of halomonas, obtained strain and application 中国科学院微生物研究所 2024-05-14 CN claimed
CN-117683285-B Oil-resistant high-dimensional-precision turnout rubber backing plate and preparation method thereof 河北铁科翼辰新材科技有限公司 2024-05-03 CN claimed
CN-115361505-B Scene self-adaptive AEC target brightness control method 豪威集成电路(成都)有限公司 2024-04-30 CN claimed
CN-117683285-A Oil-resistant high-dimensional-precision turnout rubber backing plate and preparation method thereof 河北铁科翼辰新材科技有限公司 2024-03-12 CN claimed
WO-2023158052-A1 NOVEL SYNTHETIC PROMOTER, AND METHOD FOR PRODUCING DAPTOMYCIN USING SAME 건국대학교 산학협력단 2023-08-24 WO claimed
CN-116088516-A Three-dimensional path planning method for underwater vehicle based on improved particle swarm optimization 中国人民解放军国防科技大学 2023-05-09 CN claimed
CN-112304754-B Shale brittleness logging evaluation method considering diagenesis and pressure change 中国石油天然气股份有限公司大港油田分公司 2022-08-09 CN claimed
EP-3551182-A1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN TOPICAL INNOVATIONS B.V. (NL) 2019-10-16 EP claimed
WO-2018106108-A1 TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN KEPPEL HESSELING, Jan Marius (NL) 2018-06-14 WO claimed
US-20130005786-A1 THERAPEUTIC INVENTION KAPOOR RAJU (GB) 2013-01-03 US claimed
US-4160818-A Fluorimetric immunoassay for diphenylhydantoin TECHNICON INSTRUMENTS CORPORATION (US) 1979-07-10 US claimed
CN-116265306-B Driving support device, driving support method, and program TOYOTA MOTOR CORP. (JP) 2026-05-26 CN disclosed
US-4160818-A Fluorimetric immunoassay for diphenylhydantoin TECHNICON INSTRUMENTS CORPORATION (US) 1979-07-10 US disclosed
US-4105450-A SPECTRALLY SENSITIZED POSITIVE LIGHT-SENSITIVE O-QUINONE DIAZIDE CONTAINING COMPOSITION FUJI PHOTO FILM CO., LTD. (JP) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005786-A1 THERAPEUTIC INVENTION AQP4, PMP22, NHERF1 CYP2C9 2791/4885MAPT 1803/4885BLM 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.